BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32789755)

  • 1. Detection of distant metastases in rectal cancer: contrast-enhanced CT vs whole body MRI.
    Yoon JH; Yu MH; Hur BY; Park CM; Lee JM
    Eur Radiol; 2021 Jan; 31(1):104-111. PubMed ID: 32789755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of whole-body diffusion-weighted MRI (WB-DWI/MRI) in diagnosis, staging and follow-up of gastric cancer, in comparison to CT: a pilot study.
    De Vuysere S; Vandecaveye V; De Bruecker Y; Carton S; Vermeiren K; Tollens T; De Keyzer F; Dresen RC
    BMC Med Imaging; 2021 Feb; 21(1):18. PubMed ID: 33546626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
    Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
    Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT.
    Michielsen K; Vergote I; Op de Beeck K; Amant F; Leunen K; Moerman P; Deroose C; Souverijns G; Dymarkowski S; De Keyzer F; Vandecaveye V
    Eur Radiol; 2014 Apr; 24(4):889-901. PubMed ID: 24322510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
    Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C
    Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging.
    Johnston EW; Latifoltojar A; Sidhu HS; Ramachandran N; Sokolska M; Bainbridge A; Moore C; Ahmed HU; Punwani S
    Eur Radiol; 2019 Jun; 29(6):3159-3169. PubMed ID: 30519933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-body MRI versus an FDG-PET/CT-based reference standard for staging of paediatric Hodgkin lymphoma: a prospective multicentre study.
    Spijkers S; Littooij AS; Kwee TC; Tolboom N; Beishuizen A; Bruin MCA; Elias SG; van de Brug T; Enríquez G; Sábado C; Miller E; Granata C; de Lange C; Verzegnassi F; Greer MC; de Keizer B; Nievelstein RAJ
    Eur Radiol; 2021 Mar; 31(3):1494-1504. PubMed ID: 32880696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-body diffusion-weighted MRI for operability assessment in patients with colorectal cancer and peritoneal metastases.
    Dresen RC; De Vuysere S; De Keyzer F; Van Cutsem E; Prenen H; Vanslembrouck R; De Hertogh G; Wolthuis A; D'Hoore A; Vandecaveye V
    Cancer Imaging; 2019 Jan; 19(1):1. PubMed ID: 30616608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial M Staging of Rectal Cancer: FDG PET/MRI with a Hepatocyte-specific Contrast Agent versus Contrast-enhanced CT.
    Yoon JH; Lee JM; Chang W; Kang HJ; Bandos A; Lim HJ; Kang SY; Kang KW; Ryoo SB; Jeong SY; Park KJ
    Radiology; 2020 Feb; 294(2):310-319. PubMed ID: 31793850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?
    Chen W; Jian W; Li HT; Li C; Zhang YK; Xie B; Zhou DQ; Dai YM; Lin Y; Lu M; Huang XQ; Xu CX; Chen L
    Magn Reson Imaging; 2010 Jun; 28(5):613-20. PubMed ID: 20418042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of whole-body MRI including diffusion-weighted sequences in the initial staging of breast cancer patients at high risk of metastases in comparison with PET-CT: a prospective cohort study.
    Hottat NA; Badr DA; Ben Ghanem M; Besse-Hammer T; Lecomte SM; Vansteelandt C; Lecomte SL; Khaled C; De Grove V; Salem Wehbe G; Cannie MM; Jani JC
    Eur Radiol; 2024 Jan; 34(1):165-178. PubMed ID: 37555959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT.
    Schmidt GP; Schoenberg SO; Schmid R; Stahl R; Tiling R; Becker CR; Reiser MF; Baur-Melnyk A
    Eur Radiol; 2007 Apr; 17(4):939-49. PubMed ID: 16951929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of whole-body PET/CT, dedicated high-resolution head and neck PET/CT, and contrast-enhanced CT in preoperative staging of clinically M0 squamous cell carcinoma of the head and neck.
    Rodrigues RS; Bozza FA; Christian PE; Hoffman JM; Butterfield RI; Christensen CR; Heilbrun M; Wiggins RH; Hunt JP; Bentz BG; Hitchcock YJ; Morton KA
    J Nucl Med; 2009 Aug; 50(8):1205-13. PubMed ID: 19617339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast.
    Catalano OA; Daye D; Signore A; Iannace C; Vangel M; Luongo A; Catalano M; Filomena M; Mansi L; Soricelli A; Salvatore M; Fuin N; Catana C; Mahmood U; Rosen BR
    Int J Oncol; 2017 Jul; 51(1):281-288. PubMed ID: 28535000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-body-MR imaging including DWIBS in the work-up of patients with head and neck squamous cell carcinoma: a feasibility study.
    Noij DP; Boerhout EJ; Pieters-van den Bos IC; Comans EF; Oprea-Lager D; Reinhard R; Hoekstra OS; de Bree R; de Graaf P; Castelijns JA
    Eur J Radiol; 2014 Jul; 83(7):1144-1151. PubMed ID: 24768188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system.
    Schmidt GP; Baur-Melnyk A; Herzog P; Schmid R; Tiling R; Schmidt M; Reiser MF; Schoenberg SO
    Invest Radiol; 2005 Dec; 40(12):743-53. PubMed ID: 16304476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additional Value of Integrated
    Yoo J; Lee JM; Yoon JH; Joo I; Lee DH
    Korean J Radiol; 2021 May; 22(5):714-724. PubMed ID: 33660461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-body diffusion-weighted magnetic resonance imaging versus FDG-PET/CT for initial lymphoma staging: systematic review on diagnostic test accuracy studies.
    Regacini R; Puchnick A; Shigueoka DC; Iared W; Lederman HM
    Sao Paulo Med J; 2015; 133(2):141-50. PubMed ID: 25789779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of MRI Sequences in Whole-Body PET/MRI for Staging of Patients With High-Risk Prostate Cancer.
    Metser U; Chan R; Veit-Haibach P; Ghai S; Tau N
    AJR Am J Roentgenol; 2019 Feb; 212(2):377-381. PubMed ID: 30332285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Staging of colon cancer: whole-body MRI vs. whole-body PET-CT--initial clinical experience.
    Squillaci E; Manenti G; Mancino S; Cicciò C; Calabria F; Danieli R; Schillaci O; Simonetti G
    Abdom Imaging; 2008; 33(6):676-88. PubMed ID: 18373114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.